BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep 2004;6:177-83. [PMID: 15066228 DOI: 10.1007/s11912-004-0047-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Duan C, Zhang W, Lu J, Wu H, Liu M, Zhu W. DNA repair gene XRCC3 Thr241Met polymorphism and hepatocellular carcinoma risk. Tumor Biol 2013;34:2827-34. [DOI: 10.1007/s13277-013-0841-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
2 Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15(26): 3210-3216 [PMID: 19598295 DOI: 10.3748/wjg.15.3210] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 93] [Article Influence: 7.2] [Reference Citation Analysis]
3 Bai M, Reynolds NR, Mccorkle R. The promise of clinical interventions for hepatocellular carcinoma from the west to mainland China. Pall Supp Care 2013;11:503-22. [DOI: 10.1017/s1478951512001137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
4 Peng Q, Li S, Lao X, Chen Z, Li R, Qin X. Interleukin-12B+1188A/C polymorphism contributes to increased hepatocellular carcinoma susceptibility: Evidence from a meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2014;38:735-43. [DOI: 10.1016/j.clinre.2014.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Iida T, Shiba H, Misawa T, Ohashi T, Eto Y, Yanaga K. Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. Cancer Science 2008;99:2097-103. [DOI: 10.1111/j.1349-7006.2008.00953.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
6 Boussouar S, Itti E, Lin SJ, Decaens T, Evangelista E, Chiaradia M, Chalaye J, Baranes L, Calderaro J, Laurent A. Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation. Cancer Imaging. 2016;16:4. [PMID: 26883745 DOI: 10.1186/s40644-016-0062-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
7 Lv L, Wang P, Zhou X, Sun B. Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol 2013;34:1451-9. [PMID: 23564481 DOI: 10.1007/s13277-013-0649-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
8 Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep 2010;12:186-92. [PMID: 20425078 DOI: 10.1007/s11912-010-0094-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
9 Kassahun WT, Günl B, Jonas S, Ungemach FR, Abraham G. Altered liver α1-adrenoceptor density and phospholipase C activity in the human hepatocellular carcinoma. Eur J Pharmacol 2011;670:92-5. [PMID: 21910987 DOI: 10.1016/j.ejphar.2011.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]